Hutchmed (china) Ltd cash flow statement

In fiscal 2025, Hutchmed (china) Ltd's operations generated −$64.7m of cash; it spent $14.1m on capital projects, leaving free cash flow of −$78.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Hutchmed (china) Ltd: cash flow statement, annual
Fiscal year	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	8	−9	−10	−9	−33	−81	−62	−204	−269	219	0	−65
Depreciation and amortisation	1	2	2	3	4	5	6	7	9	8	12	13
Stock-based pay	—	0	3	3	11	9	16	36	40	30	30	14
Capital spending	4	3	4	5	6	9	8	16	37	33	18	14
Free cash flow	5	−13	−14	−14	−39	−89	−70	−221	−305	187	−17	−79
Free cash flow after stock pay	—	−13	−17	−17	−50	−99	−86	−257	−345	157	−48	−93
Share buybacks	—	2	1	1	5	0	13	27	48	9	36	—
Shares issued	3	1	111	302	4	0	319	717	0	5	1	2

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ADMA vs HCM HCM vs TARS HCM vs MIRM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Hutchmed (china) Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Hutchmed (china) Ltd.